POPi measures and evaluates pharmaceutical outcomes, produces evidence, and makes recommendations to decision makers for improved clinical and public policy medication use. Within the scope of this theme, we also provide expertise in clinical pharmacology, pædiatric pharmacology, personalized medicine, pharmacogenomics, and population therapeutics.
Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia
Synopsis: This research details the burden of asthma in British Columbia (BC) using health care utilization databases and is evaluating a strategy to reduce unnecessary emergency department visits.
The strategy being developed can be readily implemented in primary care and hospital settings, in order to reduce future severe asthma exacerbations. This work will arm clinicians, parents and decision makers with the necessary information to improve the care of children with repeated asthma exacerbations.
Therapeutic Evaluation Unit (TEU)
Synopsis: The Therapeutic Evaluation Unit (TEU) is a clinical research and evaluation unit funded by the Provincial Health Services Authority (PHSA).
The TEU's mission is to provide healthcare decision makers, clinicians and patients with up-to-date, evidence-based information concerning the effectiveness, safety and cost management of prescription drugs and other healthcare technologies. The TEU is evaluating drugs and other health technologies to determine whether these technologies improve the quality of healthcare delivered by PHSA agencies or improve patient outcomes.
- Antipsychotic use in British Columbian children
- Hemoglobin A1C testing frequency and patient outcomes
- Effectiveness of tiotropium in chronic obstructive pulmonary disease
- Isotretinoin and the risk of inflammatory bowel disease
- A Cochrane systematic review looking at aspirin for the primary prevention of cardiovascular disease
- Use of palivizumab for prevention of severe lower respiratory tract infections in children
- Optimizing chronic hepatitis C treatment using pharmacogenomic biomarkers
- Use of calcium channel blockers to prevent prostate cancer metastases
- A number of projects addressing ocular adverse events including: bisphosphonates and the risk of eye inflammation, fluoroquinolones and the risk of retinal detachment, and cardiovascular risks due to bevacizumab and ranibizumab when used in patients with acute macular degeneration.